Ignite Creation Date:
2024-05-06 @ 2:15 AM
Last Modification Date:
2024-10-26 @ 11:15 AM
Study NCT ID:
NCT02001363
Status:
UNKNOWN
Last Update Posted:
2016-02-05
First Post:
2013-11-27
Brief Title:
Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury
Sponsor:
Chen Wei Ren MD
Organization:
Chinese PLA General Hospital
Study Overview
Official Title:
Protective Effect of Glucagonlike Peptide-1 on Reperfusion Injury in Patients With Acute Myocardial Infarction
Status:
UNKNOWN
Status Verified Date:
2016-02
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The investigators planned to research the cardioprotective effects of intravenous liraglutide on reperfusion injury
Detailed Description:
Acute myocardial infarction is a major cause of mortality and morbidity Primary percutaneous coronary intervention pPCI is currently the most effective treatment strategy in acute myocardial infarction However a sizable number of patients fail to restore optimal myocardial reperfusion mostly because of the no-reflow phenomenon Glucagon-like peptide-1 GLP-1 is an incretin hormone that regulates plasma glucose and recently GLP-1 analogues have been introduced for the treatment of type-2 diabetes In experimental studies GLP-1 or its analogues protect against reperfusion injury-induced cell death Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction LiraglutideGLP-1 is safe and effective to reduce weightserum lipid levels and blood pressure Liraglutide can reduce cardiac rupture 12 of 60 versus 46 of 60 P00001 and infarct size 212 versus 293 P002 and improved cardiac output 12406 versus 9706 mlmin P0002 in normal and diabetic mice The investigators planned to research the cardioprotective effects of intravenous liraglutide administered prior to reperfusion and continued after restoration of coronary blood flow in patients with STEMI undergoing pPCI
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ChinaPLAGH | OTHER | ChinaPLAGH | None |